We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328202

CAS#: 89482-00-8

Description: Zaltoprofen, also known as CN-100, is a non-steroidal anti-inflammatory drug that has potent inhibitory action against nociceptive responses.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-30. Prices are subject to change without notice.

Zaltoprofen is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 328202
Name: Zaltoprofen
CAS#: 89482-00-8
Chemical Formula: C17H14O3S
Exact Mass: 298.0664
Molecular Weight: 298.356
Elemental Analysis: C, 68.44; H, 4.73; O, 16.09; S, 10.75

Synonym: Zaltoprofen; CN-100; CN100; CN 100

IUPAC/Chemical Name: 2-(10-oxo-10,11-dihydrodibenzo[b,f]thiepin-2-yl)propanoic acid


InChi Code: InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)

SMILES Code: CC(C1=CC=C(C(C2)=C1)SC3=CC=CC=C3C2=O)C(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Jia L, Hu C, Wang H, Liu Y, Liu X, Zhang YY, Li W, Wang LX, Cao YF, Fang ZZ. Chirality Influence of Zaltoprofen Towards UDP-Glucuronosyltransferases (UGTs) Inhibition Potential. Chirality. 2015 Jun;27(6):359-63. doi: 10.1002/chir.22436. Epub 2015 Apr 22. PubMed PMID: 25903196.

2: Mishra R, Prabhavalkar KS, Bhatt LK. Preparation, optimization, and evaluation of Zaltoprofen-loaded microemulsion and microemulsion-based gel for transdermal delivery. J Liposome Res. 2016 Dec;26(4):297-306. doi: 10.3109/08982104.2015.1120746. Epub 2016 Jan 19. PubMed PMID: 26785055.

3: Cui H, Quan P, Zhao H, Wen X, Song W, Xiao Y, Zhao Y, Fang L. Mechanism of Ion-Pair Strategy in Modulating Skin Permeability of Zaltoprofen: Insight from Molecular-Level Resolution Based on Molecular Modeling and Confocal Laser Scanning Microscopy. J Pharm Sci. 2015 Oct;104(10):3395-403. doi: 10.1002/jps.24543. Epub 2015 Jun 17. PubMed PMID: 26349639.

4: Baek JS, Lim JH, Kang JS, Shin SC, Jung SH, Cho CW. Enhanced transdermal drug delivery of zaltoprofen using a novel formulation. Int J Pharm. 2013 Sep 10;453(2):358-62. doi: 10.1016/j.ijpharm.2013.05.059. Epub 2013 Jun 4. PubMed PMID: 23747435.

5: Cho IJ, Lee CW, Lee MY, Kang MR, Yun J, Oh SJ, Han SB, Lee K, Park SK, Kim HM, Jung SH, Kang JS. Differential anti-inflammatory and analgesic effects by enantiomers of zaltoprofen in rodents. Int Immunopharmacol. 2013 Aug;16(4):457-60. doi: 10.1016/j.intimp.2013.05.008. Epub 2013 May 27. PubMed PMID: 23721690.

6: Cui H, Quan P, Zhou Z, Fang L. Development of a drug-in-adhesive patch combining ion pair and chemical enhancer strategy for transdermal delivery of zaltoprofen: pharmacokinetic, pharmacodynamic and in vitro/in vivo correlation evaluation. Drug Deliv. 2016 Jul 16:1-10. [Epub ahead of print] PubMed PMID: 27257038.

7: Pawar S, Pande V. Oleic Acid Coated Gelatin Nanoparticles Impregnated Gel for Sustained Delivery of Zaltoprofen: Formulation and Textural Characterization. Adv Pharm Bull. 2015 Nov;5(4):537-48. doi: 10.15171/apb.2015.073. Epub 2015 Nov 30. PubMed PMID: 26819927; PubMed Central PMCID: PMC4729344.

8: Shah HA, Patel RP. Statistical modeling of zaltoprofen loaded biopolymeric nanoparticles: Characterization and anti-inflammatory activity of nanoparticles loaded gel. Int J Pharm Investig. 2015 Jan-Mar;5(1):20-7. doi: 10.4103/2230-973X.147229. PubMed PMID: 25599029; PubMed Central PMCID: PMC4286831.

9: Wang H, Ji J, Zeng S. Biosynthesis and stereoselective analysis of (-)- and (+)-zaltoprofen glucuronide in rat hepatic microsomes and its application to the kinetic analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 15;879(24):2430-6. doi: 10.1016/j.jchromb.2011.06.043. Epub 2011 Jul 6. PubMed PMID: 21775222.

10: Kohno T. Zaltoprofen inhibits bradykinin-mediated enhancement of glutamate receptor activity in substantia gelatinosa neurons. Anesth Analg. 2011 Aug;113(2):412-6. doi: 10.1213/ANE.0b013e31821c693c. Epub 2011 Apr 25. PubMed PMID: 21519044.